Christopher Hite

Board Director

Director

Insider activity · 24 months0 buys3 salesCumulative net flow

Nov 24 · 0 buys · 0 salesDec 24 · 0 buys · 0 salesJan 25 · 0 buys · 0 salesFeb 25 · 0 buys · 0 salesMar 25 · 0 buys · 0 salesApr 25 · 0 buys · 0 salesMay 25 · 0 buys · 0 salesJun 25 · 0 buys · 0 salesJul 25 · 0 buys · 0 salesAug 25 · 0 buys · 0 salesSept 25 · 0 buys · 0 salesOct 25 · 0 buys · 0 salesNov 25 · 0 buys · 0 salesDec 25 · 0 buys · 0 salesJan 26 · 0 buys · 0 salesFeb 26 · 0 buys · 0 salesMar 26 · 0 buys · 0 salesApr 26 · 0 buys · 0 salesMay 26 · 0 buys · 0 salesJun 26 · 0 buys · 0 salesJul 26 · 0 buys · 0 salesAug 26 · 0 buys · 1 saleSept 26 · 0 buys · 2 salesOct 26 · 0 buys · 0 sales

Total declarations

Companies

▲ Purchases (0 ops.)

—

▼ Sales (5 ops.)

€10.3M

Latest filing published 24 Sept 2026 for Royalty Pharma plc, €4.9M. Read the official filing

Filing timeline

BuySale

Christopher Hite

Insider track record

Disclosed buys

Disclosed sells

Not enough buy signals with a settled T+90 horizon to measure a track record yet.

Signal history

No signal scores available.

Christopher Hite: trading record in brief

Christopher Hite, listed as board member, has filed trades across 2 companies (mainly through SEC (Form 4)), most often in Royalty Pharma plc and Acceleron Pharma Inc. We count 14 filings; the first trade dates from 19 November 2021 and the latest from 22 September 2026.

Sales make up the whole of the open-market record (5 sales, €10.3M). The amount is not disclosed for 2 filings. Besides market trades, the filings include 5 share grants. 2026 to date brings no purchases and 5 sales.

The record was last updated on 24 September 2026 with an open-market sale (€4.9M) in Royalty Pharma plc. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. For comparison, the SEC allows two business days to file a Form 4. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.